We investigated the changes in sexual function in male patients with germ cell tumor continuously disease free after one or two courses of high-dose chemotherapy with hematopoietic stem cell support. A questionnaire was mailed to 35 patients, and 30 patients sent it back. Sexuality was considered a problem by 10 patients (33%), but no patients considered sexuality a major problem. Erection was more difficult to achieve in seven patients (23%) and 10 patients (33%) experienced increased difficulty in maintaining an erection. Eight patients (27%) had the experience of less intensive and less frequent orgasm. In all, 13 patients (43%) thought that both the disease and treatment had worsened their sexual capacity, but 20 patients (67%) were satisfied with their sex life. Most of the patients (63%) considered that insufficient information and counselling had been given by their physicians about the sexual sequelae of therapy. However, the amount of information about the disease and treatment was considered good by 77 and 80% of the patients, respectively. This study shows that 27% of patients were not content with their ability to attain sexual satisfaction due to the illness or its treatment. Communication is an important issue and better information tools could lead to improved compliance in these patients.
(HDCT) with hematopoietic stem cell support (HSCS) on sexual function. In particular, there are few baseline data about sexual functioning after HDCT in survivors of germ cell tumors (GCTs).
A number of studies have suggested that HDCT with HSCS may be associated with a variety of abnormalities in psychological function including sexual dysfunction. An unsatisfactory sex life has been reported in 19% of patients who received chemotherapy for nonseminoma testicular cancer without retroperitoneal lymph node dissection (RPLND). 1 Sexual dissatisfaction has been reported in 14-86% of patients with leukemia/lymphoma or solid tumors after bone marrow transplantation (BMT). [2] [3] [4] [5] This difference could be for a number of reasons: method of assessing sexual function, patient populations, transplant regimens and type of disease. 6 The causes of post transplant sexual problems are uncertain but likely to be rather complex. A major difficulty in all studies of BMT-associated sexual dysfunction is to ascertain what is due to the cancer, its diagnosis and its therapy per se, and what is due to the transplant. 7 Multiple etiologies, including psychological and physical difficulties, must be considered and may play a role in sexual difficulties after autologous bone marrow transplantation (ABMT). 6 The present study investigated sexual and psychosocial changes in male patients with GCT continuously disease free after HDCT with HSCS.
Patients and methods
Sexual life was assessed using two previously employed instruments. The sexual scale of the UCLA/RAND Prostate Cancer Index, validated in the English language and described by Litwin et al, 8 was used to assess the sexual capacity of patients at the time of the study. In the questionnaire, there was also a section to evaluate physical and psychological conditions and the patients' social relations. The questions refer to the four last weeks after the compilation of the questionnaire.
The sexual questionnaire of Groningen University, described by Jonker-Pool et al, 9 referred to the time of treatment and was used to evaluate the influence of the disease and/or its treatment on sexuality, and counselling about sexual sequelae provided by medical staff during the treatment period. As the two questionnaires were developed and validated in foreign languages, the items were translated into Italian by an expert panel of physicians who followed recommendations of Guillemin et al 10 to ensure psychometric validity.
The Groningen University form was totally incorporated into the final questionnaire with a few modifications; the item relating to erection was split to assess achievement and maintenance separately; the items relating to orgasm were divided to assess intensity and frequency separately; the one relating to the usefulness of information and counselling on sexuality was given in a four-answer instead of a twoanswer format. All the items in the UCLA/RAND Prostate Cancer sexual scale were included in the final instrument with the exception of the item concerning anal intercourse.
Furthermore, six additional items explored patient perception in relation to: (a) the amount of information provided by physicians about the disease and its treatment; (b) the usefulness of information and counselling about possible treatment-related sexual disturbances; and (c) the changes in body image caused by the treatment and any discomfort because of the surgical scar.
We also asked if the patient had had 'semen cryopreservation', if he had suffered from a psychological disorder after the last treatment, and if so, what it was. The questionnaire also included a space in which patients could indicate whether any major sexuality issue had been omitted and/or make any other comment. Information about demographic data (marital status, number of cohabitants, employment and education) at the time of treatment and at the time of completing the questionnaire was requested, and patients were asked whether they used any drugs for concomitant diseases. Fertility was explored by asking information about the number of children and their dates of birth. The questionnaire started with an explanatory message containing instructions on completion, and assurance that the information provided would remain strictly confidential.
The questionnaire was mailed to 35 male patients with GCT continuously disease free after one or two courses of HDCT with HSCS, treated at the Department of Oncology and Hematology in Ravenna, between May 1987 and February 2001. In total, 30 (86%) patients sent back the questionnaire. All 30 patients are continuously disease free at a median follow-up of 73 months (range 16-181 months). One of the five patients who did not reply could Sexual functions after high-dose chemotherapy not be contacted. The median age of the responders was 27 years (range 16-42 years) at the time of treatment and 36.5 years (range 22-55 years) at the time of completing the questionnaire. A total of 28 patients had nonseminomatous GCT, and two patients had a seminoma. Six patients had primitive cancer outside the testis, three in the retroperitoneum and three in the mediastinum, respectively; no patient underwent RPLND. The prognostic score was poor risk for 16 patients, intermediate risk for four, good risk for nine patients and unknown for one. 11 The first chemotherapy segment consisted of two courses of cisplatin, etoposide and bleomycin (PEB) in two, three PEB in six, four PEB in 16, five PEB in one, three cisplatin, etoposide and ifosfamide (PEI) in one, four PEI in one, two PEB þ two POMB (cisplatin, vincristine, methotrexate, bleomycin) in one patient, and two PEB þ two PEI or two PEB þ one vinblastine, ifosfamide and cisplatin (VeIP) in other two patients, respectively. The second part of treatment consisted of two PEB in one, one VeIP in one, two VeIP in six, three VeIP in two, one PEI in two, two PEI in two patients, three PEI in four, four PEI in two patients. Further treatment was one oral etoposide in one, and two PEI in one patient.
In total, 20 patients underwent 23 courses of HDCT as salvage treatment, and 10 were treated with 14 courses of HDCT as late intensification in the first-line setting. One patient received one course of HDCT with carboplatin and etoposide (CE), 12 were treated with 18 courses of HDCT with ifosfamide, carboplatin, etoposide (ICE) with or without colony-stimulating factors (GM/G factors), while 17 patients received 18 courses of HDCT with carboplatin, etoposide, cyclophosphamide (CarboPEC).
Peripheral blood stem cells (PBSCs) mobilization was accomplished with one or two VeIP, respectively, in 10 and one patient, one PEI was used in four patients, one cyclophosphamide (CTX) in one patient and cisplatin and etoposide (PE) was used in one patient (Table 1) .
HSCS consisted of ABMT in 15 patients, PBSCs in 13 and both in two patients.
In all, 13 (43%) patients received RPLND during their long clinical course and three of them complained about poor erectile function. Out of these three patients, two received bilateral RPLND, while the other had left monolateral RPLND.
Results
Of the 35 questionnaires, 30 (86%) were returned and considered fully assessable. Only two patients were taking any medications: two, psychotherapeutic agents for depression that appeared after the diagnosis of GCT, one a hypotensive agent and one androgen hormone replacement after hemicastration. In all, 11 patients already had children before the diagnosis of cancer, three patients had children after HDCT, five patients who married at least 10 years after the diagnosis had no children and 11 patients are currently unmarried. Sociodemographic characteristics of the patients evaluated are given in Table 2 .
At the time of completing the questionnaire, only one patient considered his quality of life bad, six (20%) fair, 19 (63%) good and four (13%) very good.
Patient compliance with the questionnaire was good; 43% of the participants answered all questions, and all gave an answer to nearly 90% of the items. Only one patient wrote that the questionnaire was not exhaustive in its questioning.
UCLA/RAND sexual module
Most of the patients (73%) had been sexually active during the month before the questionnaire was administrated: four patients (13%) had less than one episode of sexual intercourse per week, seven patients (23%) one intercourse per week, 11 patients (37%) more than one intercourse per week, six patients (20%) had had no sexual intercourse during the preceding last month. Only three patients (10%) reported a low libido and three defined their sexual capacity as poor. The ability to have an erection was considered fair in 14 patients (47%) and 24 (80%) reported sufficient erection for sexual intercourse. Nocturnal penile tumescence was reported as frequent by 15 patients; 25 patients declared that their capacity to achieve orgasm was good. Sexuality was considered a problem by 10 patients (33%), but no patients considered sexuality a big problem (Table 3) . The physical and psychological conditions and the patients' social relations during the last 4 weeks after completing the questionnaire are shown in Table 4 . These items suggest that six patients considered the quality of their life fair and only one considered it bad.
Groningen module
All (93%) but two patients, who did not answer, claimed to have been sexually active before diagnosis of their disease. In total, 13 patients (43%) did not decrease sexual contact either after the illness was diagnosed, or after treatment (HDCT). After HDCT, erection was considered more difficult to achieve by seven patients (23%). A total of 10 patients (33%) found it increasingly difficult to maintain an erection after HDCT (Table 5 ). Eight patients (27%) had the experience of less intense and less frequent orgasm after HDCT. Only 10 patients (33%) reported that they had no problems in ejaculating after the last treatment. Only three patients, referred because of ejaculation failure, had received RPLND. In all, 13 patients (43%) considered that both the disease and the treatment had worsened their sexual capacity. A total of 20 patients (67%) were satisfied with their sex life. Three patients (10%) thought that their partner had been dissatisfied with their sexual life as a couple, because of the disease and/or its treatment in two cases, and for other reasons in one. Compared with the pretreatment period, the importance of sexuality was described as important as previously by 18 patients (60%) and more so by eight (26%). In all, 12 patients (40%) thought that the quality of the relationship with their partner had changed as a result of the disease.
A total of 12 patients (40%) considered that their quality of life was not influenced at all by the illness or its treatment. In all, 17 patients (57%) worked as they had prior to treatment and 17 patients (57%) considered that the illness and treatment had not worsened their family or social life.
Most of the patients (64%) considered that the information given by their physicians about the sexual sequelae of therapy was insufficient and 74% stated that they had received insufficient counselling concerning sexual problems. Only nine patients (30%) had had semen cryopreservation and at least 23% suffered from psychological problems at the end of treatment; 10% reported anxiety and three other patients (10%) reported depression.
The amount of information received about the disease and treatment was considered good by 76 and 80% of patients, respectively. A total of 67 and 80% of patients, respectively, considered receiving information and counsel- ling about sexual problems very important. In all, 13 patients (43%) considered that their body image had not worsened at all after surgery and medical therapy, and 40% felt discomfort on seeing the orchidectomy scar.
Discussion
GCTs mostly affect men in the prime of their physical, sexual and reproductive life. The vast majority of patients with GCT may expect a normal disease-free lifespan, and even those with disseminated disease can be cured completely by chemotherapy. 11 The current standard firstline chemotherapy regimen for advanced GCT consists of three-four courses of PEB. 12 Although PEB is related to symptoms of angiopathy, cavernosal blood flow seems to be unaffected. These findings and the normal visual erotic stimulation-evoked penile rigidity suggest that sexual dysfunction is more psychologically than organically induced by PEB. 12 Compared with orchidectomy alone, polychemotherapy, with or without RPLND, more often induced post treatment sexual dysfunction. Over the last decade, HDCT has been increasingly investigated as a salvage therapy for patients with relapsed or refractory GCT and as late intensification of first-line treatment for patients with poor prognosis GCT. 13 The effect on sexual and reproductive function in both male and female patients has been reported in some patients. In the study by Vose et al, 5 male patients reported a 35% incidence of inability to ejaculate and 39% incidence of inability to achieve an erection. However, overall patients had a positive outlook after treatment, with most of them being able to return to work and enjoy a fairly normal life style. Of the patients, 96% stated that they would be willing to undergo the same treatment under the same circumstances. 5 There are few studies that prospectively evaluated whether HDCT affects sexual function in a broad spectrum of diseases, mainly hematological disorders. 4, 6, 14, 15 As 27% of patients in our study were not content with their ability to obtain sexual satisfaction, clinicians should include evaluation of sexuality in the post transplant period and during follow-up.
Infertility may result from retrograde ejaculation after RPLND or as a result of the toxic effects of the chemotherapy or radiotherapy on the germ cells of the Table 4 Physical-psychological conditions and patients' social relations in the last four weeks remaining testis. A minority of patients with GCTs are infertile at diagnosis; the majority are either subfertile (with a decreased sperm count or decreased motility) or normally fertile.
11
Discussion of the several problems experienced was an important issue for 67% of patients, and counselling about sexual issues was considered important in 80% of patients. Our data emphasize the importance of assessing sexual function during patient follow-up and providing counselling to patients who report problems.
Sexual problems are nearly always caused by a combination of physiologic changes and psychological factors. In general, having a diagnosis of cancer is regarded as a critical point in life associated with long-lasting psychological effects. Even a decade after treatment, men may still suffer from anxiety, insomnia, depression and decreased sexual arousal. [16] [17] [18] [19] In comparison to age-matched men with Hodgkin's disease or leukemia, patients with testicular GCT more often report sexual problems, suggesting that the specific location of testicular GCT plays a negative role. 20 Owing to its symbolic nature, the loss of a testicle itself may influence masculinity, sexual identity and body image. 21 Although the participation rate of patients was high, it is possible that the high incidence of sexual dysfunction seen in this study is an underestimate of the extent of the problem, because patients who are functioning poorly or who are depressed may not consent to participate in studies such as this one. The time interval from the therapy to this survey is very long in many patients; nevertheless, patients replying to the questionnaire confirm that they remember all the issues concerning sexuality after treatment.
Future studies should include sequential interviews starting before HDCT and continuing in the follow-up period to define the compliance in these patients better.
